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Abstract
Background: The purpose of the present study was to explore novel biomarkers that can predict the clinical
outcome of patients before treatment or during vaccination. These would be useful for the selection of appropriate
patients who would be expected to exhibit better treatment outcomes from vaccination, and for facilitating the
development of cancer vaccine treatments.
Methods: From a single-arm, non-randomized, human leukocyte antigen (HLA)-A-status-blind phase II trial of a
vaccine treatment using three HLA-A*2402-restricted peptides for advanced pancreatic cancer (PC), we obtained
peripheral blood samples from 36 patients of an HLA-A*2402-matched group and 27 patients of an HLA-A*2402-
unmatched group.
Results: Multivariate analysis (HR = 2.546; 95% CI = 1.138 to 5.765; p = 0.0231) and log-rank test (p = 0.0036) showed
that a high expression level of programmed death-1 (PD-1) on CD4+ T cells was a negative predictive biomarker of
overall survival in the HLA-A*2402-matched group . Moreover, a high expression level of PD-1 on CD4+ T cells was a
negative predictor for the induction of cytotoxic T lymphocytes (p = 0.0007). After treatment, we found that the
upregulation of PD-1 and T cell immunoglobulin mucin-3 (Tim-3) expression on CD4+ and CD8+ T cells was significantly
associated with a poor clinical outcome in the HLA-A*2402-matched group (p = 0.0330, 0.0282, 0.0046, and 0.0068,
respectively). In contrast, there was no significant difference for these factors in the HLA-A*2402-unmatched group.
Conclusions: Our results indicate that the upregulation of PD-1 and Tim-3 expression on CD4+ and CD8+ T cells may
restrict T cell responses in advanced PC patients; therefore, combination immunotherapy with blockade of PD-1 and
Tim-3 to restore T cell responses may be a potential therapeutic approach for advanced PC patients.
Trial registration: Clinical-Trail-Registration: UMIN000008082.
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Background
Pancreatic cancer (PC) is one of the most lethal cancers,
and the majority of PC patients are diagnosed at an ad-
vanced stage due to the difficulty of early diagnosis [1].
It has been reported that advanced PC patients have a
median survival time (MST) of less than 6 months [2].
Gemcitabine (GEM) has been regarded as a standard
chemotherapeutic agent for advanced PC [3]. Although
recent advances in combination chemotherapy including
GEM and other cytotoxic agents or chemoradiotherapy
have improved the clinical outcomes of advanced PC pa-
tients, the prognosis still remains poor [4–7]. Therefore,
new treatment strategies are necessary.
Recent advances in cancer immunotherapies, such as
immune checkpoint inhibitors, have shown some dur-
able clinical responses in patients with various types of
advanced cancers [8, 9]. However, since their clinical effi-
cacy remains limited, active immunotherapies using
tumor-associated antigen (TAA)-derived epitope peptides,
which can induce tumor-specific cytotoxic T lymphocytes
(CTLs) in vivo, should be developed. The efficacy of
current immunotherapies also remains limited due to the
immunosuppressive tumor microenvironment, which leads
to TAA-specific T cell exhaustion or anergy and the escape
of tumor cells from immune attack [10]. It has been re-
ported that the expression of programmed death-1 (PD-1)
and T cell immunoglobulin mucin-3 (Tim-3), which are in-
hibitory receptors, is upregulated on exhausted T cells in
cancer patients [11, 12]. Regulatory T cells (Tregs) and
myeloid-derived suppressor cells (MDSCs) are considered
to be pivotal components of immunosuppressive cells
[13, 14]. Hence, there is a desperate need to identify
predictive biomarkers that can enable, prior to treat-
ment, the selection of patients who are likely to re-
spond well and effectively to epitope peptides that
induce specific CTLs [15–19].
We have reported a phase II study (VENUS-PC study)
in which three epitope peptides (one derived from
oncoantigen KIF20A (RAB6KIFL)[20] and two derived
from vascular endothelial growth factor receptors
(VEGFRs)[21, 22]) in combination with GEM were
applied to advanced PC patients [23]. We verified the
safety of the treatment and its potential to induce
CTLs. We also revealed that a high CTL response
after vaccination and an injection site skin reaction
were possible biomarkers for a long survival in vacci-
nated patients [23].
The purpose of the present study was to explore novel
biomarkers for predicting the efficacy of immunother-
apies, and to apply such information to select patients
who are expected to exhibit better treatment outcomes
following vaccination. Here, we report the results of pos-
sible biomarkers for active immunotherapies and the
need for overcoming immune suppression.
Methods
Patients and study design
The detailed protocol of this phase II study has been re-
ported recently (VENUS-PC study) [23]. Briefly, the
therapy consisted of a cocktail of three therapeutic
epitope peptides in addition to GEM. Although the
peptides used in this study were human leukocyte
antigen (HLA)-A*2402-restricted peptides, all enrolled
patients, whose HLA-A status was double-blinded,
were administrated the same regime of peptide cocktail
and GEM. Each of the three peptides derived from
KIF20A-66 (KVYLRVRPLL)[20] (3 mg/shot), VEGFR1-
1084 (SYGVLLWEI)[24] (2 mg/shot), and VEGFR2-169
(RFVPDGNRI)[25] (2 mg/shot) was mixed with 1.0 ml of
incomplete Freund’s adjuvant (Montanide ISA51; Seppic,
Paris, France) and administered subcutaneously into the
thigh or axilla region once a week for the first 8 weeks,
and then once every 2 weeks. GEM was administered at a
dose of 1000 mg/m2 on days 1, 8, and 15 in a 28-day cycle.
The patients were eligible for enrollment if they were
20 years of age or older with a histologically or cytologic-
ally confirmed advanced PC, were naïve for chemother-
apy, had adequate functions of critical organs, and had a
life expectancy of 3 months or more. Written informed
consent was obtained from each patient at the time of en-
rollment. The study was carried out in accordance with
the Declaration of Helsinki on experimentations involving
human subjects, was approved by the Institutional Ethics
Review Boards of Yamaguchi University (H24-14) at each
study site, and was registered in the UMIN Clinical Trials
Registry as UMIN000008082. Among the 68 patients who
were enrolled in this study, 63 patients, for whom periph-
eral blood mononuclear cell (PBMC) samples were suffi-
ciently stocked, were evaluated in this study, and 46
patients, for whom sufficient post-treatment PBMC sam-
ples were available, were analyzed (Fig. 1).
Sample collection
A complete blood count and serum chemistry tests were
performed before treatment and every 2 weeks. For
PBMC and blood plasma isolation, 35 ml of blood was
drawn before each course. PBMCs were enriched by
density gradient centrifugation with Ficoll-Paque (Amer-
sham Pharmacia Biotech, Uppsala, Sweden). The PBMCs
and plasma were preserved in a liquid nitrogen tank
until examination.
Flow cytometry
After washing the PBMCs in FACS buffer (phosphate-
buffered saline, 1% fetal bovine serum, and 0.5 mmol/l
ethylenediaminetetraacetic acid), the following antibodies
were used for flow cytometry: VioBlue-conjugated anti-
human CD4 (clone VIT4; Miltenyi Biotec, Bergisch
Gladbach, Germany), FITC-conjugated anti-human CD8
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(clone RPA-T8; BD Biosciences, Heidelberg, Germany)
and CD25 (clone B1.49.9; Beckman Coulter, Marseille,
France), APC-conjugated anti-human PD-1 (clone
EH12.2H7; Biolegend, San Diego, CA) and CD45RA
(clone HI100; Biolegend), and PE-conjugated anti-human
Tim-3 (clone F38-2E2; Biolegend). After staining, the cells
were washed in FACS buffer and analyzed using a MACS-
Quant flow cytometer with MACSQuantify software
(Miltenyi Biotec). In this study, the percentages of PD-1+
and Tim-3+ T cells were calculated as percentages of the
total CD4+ or CD8+ T cells. Tregs were identified as CD4
+ CD45RA- CD25high cells [26] and were calculated as a
percentage of the CD4+ lymphocytes. MDSCs were iden-
tified as CD11b + CD33+ cells [27] and were calculated as
a percentage of the total PBMCs.
Measurement of the peptide-specific interferon-γ response
and plasma interleukin-6 (IL-6) level
Antigen-specific T cell responses were estimated by
enzyme-linked immunospot assays following in vitro
sensitization [28]. The numbers of peptide-specific spots
were calculated by subtracting the spot number in the con-
trol well from the spot number of wells with vaccinated
peptide-pulsed stimulator cells. Antigen-specific T cell re-
sponses were classified into four grades (-, +, ++, or +++)
according to the algorithm flow chart described in our pre-
vious report (Additional file 1: Figure S1) [29, 30]. Plasma
IL-6 levels were measured by electrochemiluminescence
immunoassays (Meso Scale Discovery, Rockville, MD) ac-
cording to the manufacturer’s instructions.
Statistical analysis
Results are expressed as the means ± standard error. Cat-
egorical variables were compared by using Chi-square
and Fisher’s exact tests. Survival curves were analyzed by
the Kaplan-Meier method and the log-rank test. Poten-
tial prognostic factors for survival were determined by
univariate analysis, and were assessed by multivariate
analysis with the Cox proportional hazards model. The
Wilcoxon matched-pairs test, Mann-Whitney U-tests,
Fig. 1 CONSORT diagram. Scheme showing an HLA-A-status double-blind, biologically randomized phase II study of three therapeutic epitope
peptides combined with gemcitabine as a first-line therapy for advanced pancreatic cancer (VENUS-PC study)
Shindo et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:36 Page 3 of 10
and Spearman test were used to assess the differences
and correlation were used to assess the differences be-
tween the study groups. Statistical analyses were per-
formed with JMP V11 (SAS, Cary, NC) and GraphPad
Prism V5.0 (GraphPad Software, Inc., San Diego, CA). A
p < 0.05 was considered to be statistically significant.
Results
Clinical outcomes
Sixty-three patients who had a sufficient PBMC sample
were evaluated in this study (Fig. 1). The patient character-
istics are summarized in Table 1. There were no significant
differences between the patients of the HLA-A*2402-
matched group and the patients of the HLA-A*2402-un-
matched group for age, gender, disease stage, and tumor
markers (Table 1).
Predictive factors affecting overall survival (OS) with
immunotherapy in the HLA-A*2402-matched group
We classified the patients into two groups: a long-
survival group (patients with a survival of >1 year) and a
short-survival group (patients with a survival of <1 year).
To explore predictive biomarkers for this vaccine ther-
apy, we analyzed the parameters of age, gender, disease
stage, hemoglobin (Hb), neutrophil-lymphocyte ratio
(NLR), carcinoembryonic antigen (CEA), carbohydrate
antigen 19-9 (CA19-9), IL-6, PD-1+ CD4+ T cells, Tim-
3+ CD4+ T cells, PD-1+ CD8+ T cells, Tim-3+ CD8+ T
cells, Tregs, and MDSCs in the HLA-A*2402-matched
group. The applied cutoffs for the assessed parameters
were derived based on the median values. In the univariate
analysis, age (≥65 years; hazard ratio (HR) = 2.150; 95%
confidence interval (CI) = 1.058 to 4.396; p = 0.0345)
and the expression level of PD-1 on CD4+ T cells
(≥1.83; HR = 2.962; 95% CI = 1.383 to 6.471; p = 0.0054)
were significant prognostic factors associated with OS
(Table 2). In the multivariate analysis with the Cox pro-
portional hazards model, only the expression level of PD-
1 on CD4+ T cells (≥1.83; HR = 2.546; 95% CI = 1.138 to
5.765; p = 0.0231) remained associated with poor OS
(Table 2). In the HLA-A*2402-matched group, the 1-year
survival rate and MST of the 16 patients with a high ex-
pression level of PD-1 on CD4+ T cells were significantly
worse than those of the 20 patients with a low expression
level of PD-1 on CD4+ T cells (6.3% vs. 45.0% and
7.9 months vs. 11.3 months, respectively; log-rank
test, p = 0.0036; Fig. 2a). In contrast, among the 27
patients of the HLA-A*2402-unmatched group, there
was no difference in these parameters between those
with a high or low expression level of PD-1 on CD4+
T cells (Fig. 2b; p = 0.1191).
Relationship to CTL induction
To compare the prognostic factors according to the
numbers of peptide-specific response, the parameters of
age, gender, disease stage, NLR, C-reactive protein
(CRP), IL-6, PD-1+ CD4+ T cells, Tim-3+ CD4+ T cells,
PD-1+ CD8+ T cells, Tim-3+ CD8+ T cells, Tregs, and
MDSCs were evaluated in the HLA-A*2402-matched
group. We conducted a vaccine trial using multiple epi-
tope peptides. Therefore, we compared these factors ac-
cording to multiple CTL responses, because it has been
reported that high CTL responses to multiple peptides
are associated with better prognosis [29, 31]. A signifi-
cantly high NLR (3.61 ± 0.32 vs. 2.14 ± 0.16; p = 0.0007),
high expression level of PD-1 on CD4+ T cells (3.46 ±
0.56 vs. 1.58 ± 0.17; p = 0.0007), and high number of
Tregs (2.41 ± 0.28 vs. 1.64 ± 0.13; p = 0.0121) were ob-
served in the low-CTL-response group when compared
to the high-CTL-response group (Table 3).
Next, we evaluated these factors according to the pa-
tients who showed no CTL response and the patients who
showed CTL responses to one or more peptides. A signifi-
cantly high NLR (3.91 ± 0.49 vs. 2.33 ± 0.17; p = 0.0153),
and CRP (1.89 ± 0.63 vs. 0.63 ± 0.18; p = 0.0153) were ob-
served in the low-CTL-response group when compared to
the high-CTL-response group (Additional file 2: Table S1).
PD-1 and Tim-3 expression on CD4+ and CD8+ T cells
after the 3rd cycle of treatment
We classified the patients into two groups: a long-
survival group and a short-survival group. We evaluated
the PBMCs after the 3rd cycle to evaluate the expression
of PD-1 and Tim-3 on CD4+ and CD8+ T cells in 25 pa-
tients of the HLA-A*2402-matched group and 21 pa-
tients of the HLA-A*2402-unmatched group (Fig. 1). In
the HLA-A*2402-matched group, the percentages of
Table 1 Baseline characteristics
HLA-A*24:02 HLA-A*24:02 p-value
matched unmatched
Number of patients 36 27
Age, years 62.9 ± 2.1 63.4 ± 2.1 0.7072
Gender 0.3074
Male 17 (47.2%) 17 (63.0%)
Female 19 (52.8%) 10 (37.0%)
Stage (UICC) 0.7439
III 7 (19.4%) 5 (18.5%)
IV 26 (72.2%) 21 (77.8%)
Recurrence 3 (8.3%) 1 (3.7%)
Tumor marker
CEA 369.2 ± 247.9 8.5 ± 2.1 0.1722
CA19-9 3870.1 ± 1972.7 3643.2 ± 1444.7 0.0718
Abbreviations: HLA human leukocyte antigen, UICC Union for International Cancer
Control, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9
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PD-1+ CD4+ and Tim-3+ CD4+ T cells in the patients
of the short-survival group (n = 19; 3.1% ± 0.4% and
4.4% ± 0.5%, respectively) were significantly higher than in
the patients of the long-survival group (n = 6; 1.4% ± 0.7%
and 2.3% ± 0.4%, respectively; p = 0.0330 and p = 0.0282,
respectively; Fig. 3b and 3e).
Similarly, in the HLA-A*2402-matched group, the per-
centages of PD-1+ CD8+ and Tim-3+ CD8+ T cells in
the patients of the short-survival group (7.4% ± 1.7% and
7.6% ± 1.1%, respectively) were also significantly higher than
in the patients of the long-survival group (2.0% ± 0.6% and
2.7% ±0.6%, respectively; p = 0.0046 and p = 0.0068, respect-
ively; Fig. 3h and 3k).
In contrast, there was no significant difference for
these factors in the HLA-A*2402-unmatched group
(Fig. 3c, 3f, 3i, and 3l).
Correlation between PD-1 and Tim-3 expression on CD4+
and CD8+ T cells in the patients with HLA-A*2402-
matched group
We assessed the correlation between PD-1 and Tim-3 ex-
pression on CD4+ and CD8+ T cells in the patients with
HLA-A*2402-matched group after the treatment. There
was no correlation between PD-1 and Tim-3 expression on
CD4 T cells (r = 0.3015, p = 0.1430) (Additional file 3:
Figure S2a). However, PD-1 expression on CD8 T cells was
significantly correlated with Tim-3 expression on CD8 T
cells (r = 0.5385, p = 0.0055) (Additional file 3: Figure S2b).
Changes in the CD4+ CD45RA- CD25high cells (Tregs) and
CD11b + CD33+ cells (MDSCs)
We classified the patients into two groups: a long-
survival group and a short-survival group. We assessed
Table 2 Univariate and multivariate analyses of overall survival (n = 36 HLA-A*2402-matched patients)
Variables Univariate analysis Multivariate analysis
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Age ≥65 2.150 1.058 to 4.396 0.0345 1.691 0.798 to 3.588 0.1689
Gender male/female 1.193 0.581 to 2.436 0.6271
Stage III/IV and Recurrence 0.743 0.275 to 1704 0.5033
Hb ≥13.2 0.724 0.350 to 1.515 0.3859
NLR ≥2.48 1.514 0.756 to 3.018 0.2384
CEA ≥5.3 1.791 0.879 to 3.813 0.1095
CA19-9 ≥541 1.853 0.862 to 3.935 0.1120
IL-6 ≥0.97 0.906 0.454 to 1.851 0.7816
PD-1+ CD4+ ≥1.83 2.962 1.383 to 6.471 0.0054 2.546 1.138 to 5.765 0.0231
Tim-3+ CD4+ ≥2.54 0.741 0.362 to 1.522 0.4091
PD-1+ CD8+ ≥4.73 1.892 0.925 to 3.932 0.0803
Tim-3+ CD8+ ≥4.58 0.881 0.429 to 1.799 0.7269
Treg ≥1.93 0.880 0.420 to 1.794 0.7268
MDSC ≥15.07 1.267 0.638 to 2.555 0.4981
Statistical significant results are highlighted in bold letters
Abbreviations: HLA human leukocyte antigen, CI confidence interval, Hb hemoglobin, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, NLR
neutrophil lymphocyte ration, IL-6 interleukin-6, PD-1 Programmed death-1, Tim-3 T cell immunoglobulin mucin-3, Treg Regulatory T cell, MDSC Myeloid-derived
suppressor cell
Fig. 2 Overall survival according to a biomarker. Overall survival rates of patients in the HLA-A*2402-matched group (a) and HLA-A*2402-unmatched
group (b) were analyzed by the Kaplan-Meier method for low (dotted line) or high (solid line) expression levels of PD-1 on CD4+ T cells
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negative immune factors, focusing on Tregs and
MDSCs, in the 46 patients of this study before and after
the 3rd cycle treatment (Fig. 1). There was no significant
difference before and after treatment (Additional file 4:
Figure S3a and S3d). Next, we evaluated the prognostic
differences between these factors according to the
HLA-A*2402-matched group and the HLA-A*2402-
unmatched group. Before and after treatment, there
was no significant difference in the percentages of
Tregs and MDSCs between the patients of the long-
survival group and the patients of the short-survival
group in the HLA-A*2402-matched group and the HLA-
A*2402-unmatched group (Additional file 4: Figure S3b,
S3c, S3e, and S3f).
Discussion
Due to the very rapid and impressive progress in the
area of cancer immunology [32], a large number of novel
vaccine approaches for the treatment of cancer are being
developed [33, 34]. However, useful biomarkers that can
predict a better clinical outcome from immunotherapy
have not yet been identified [15]. In this study, we
investigated novel predictive biomarkers for immuno-
therapy by comparing the prognosis of 63 patients. We
used HLA-A*2402-restricted peptides in this study. As
such, the 36 patients in the HLA-A*2402-matched group
are considered to comprise an immunological treatment
group, while the 27 patients in the HLA-A*2402-un-
matched group are considered to comprise a control
group. The results of this study are useful because we
could demonstrate the potential effectiveness of a pep-
tide vaccine according to some biomarkers that could
predict responsiveness to the vaccine treatment.
Firstly, a high expression level of PD-1 on CD4+ T
cells might be the most useful predictor of poor OS, as
seen by multivariate analysis with the Cox regression
model (p = 0.0231; Table 2), and the log-rank test also
showed that patients with a high expression level of PD-1
on CD4+ T cells had poorer OS than those with a low ex-
pression level of PD-1 on CD4+ T cells (p = 0.0036;
Fig. 2a). However, in the HLA-A*2402-unmatched group,
there was no difference between the patients with a
high or low expression level of PD-1 on CD4+ T cells
(p = 0.1191; Fig. 2b). These results support our hypothesis
that a high expression level of PD-1 on CD4+ Tcells could
be used as a biomarker for response to immunotherapy.
PD-1 is a key immune checkpoint receptor that is
expressed on activated T cells. PD-1 ligand 1 (PD-L1) is
expressed on tumor cells in various cancers, and this ex-
pression on tumors is thought to contribute to tumor
immune evasion [35]. Tim-3 is also an inhibitory recep-
tor that is expressed on type 1 helper T cells and CTLs
[36]. T cell exhaustion is a state of T cell dysfunction in
the tumor microenvironment. It has been reported that
the expression of PD-1 and Tim-3 on exhausted T cells
results in reduced proliferation and effector functions in
tumors [37]. The patients with a high expression level of
PD-1 on CD4+ T cells might be unable to maintain the
response of adaptive immune cells against cancer by vac-
cination. In this study, the induction of CTLs was also
reduced in those with a high expression level of PD-1 on
CD4+ T cells (Table 3). These results indicate that restor-
ation of the insufficient antitumor immune response in
patients with a high expression level of PD-1 on CD4+ T
cells may be a viable approach for further improving the
clinical efficacy of cancer immunotherapy.
After treatment, we found that the upregulation of PD-1
and Tim-3 expression on CD4+ T cells was significantly
associated with a poor prognosis in the HLA-A*2402-
matched group (p = 0.0330 and p = 0.0282, respectively;
Fig. 3b and 3e). However, among the 21 patients of the
HLA-A*2402-unmatched group, there was no significant
difference between the patients with a high or low expres-
sion level of PD-1 or Tim-3 on CD4+ T cells. Similar to
these results of PD-1 and Tim-3 expression on CD4+ T
cells, after treatment, we found that the upregulation of
Table 3 Comparison of prognostic factors according to the
numbers of peptide-specific responses (n = 36 HLA-A*2402-
matched patients)
Variables The number of peptide
specific response
p-value
0 or 1 2 or 3
the number of patients 10 26








NLR 3.61 ± 0.32 2.14 ± 0.16 0.0007
CRP 1.39 ± 0.48 0.58 ± 0.17 0.1425
IL-6 2.11 ± 0.70 19.40 ± 17.32 0.7640
PD-1+ CD4+ T cell 3.46 ± 0.56 1.58 ± 0.17 0.0007
Tim-3+ CD4+ T cell 3.30 ± 0.53 3.71 ± 0.68 0.8184
PD-1+ CD8+ T cell 5.63 ± 0.74 4.05 ± 0.45 0.0689
Tim-3+ CD8+ T cell 5.37 ± 0.98 4.77 ± 0.49 0.7108
Treg 2.41 ± 0.28 1.64 ± 0.13 0.0121
MDSC 17.34 ± 1.70 14.29 ± 0.78 0.1005
Statistical significant results are highlighted in bold letters
Abbreviations: HLA human leukocyte antigen, CI confidence interval, UICC
Union for International Cancer, NLR neutrophil lymphocyte ration, CRP
C-reactive protein, IL-6 interleukin-6, PD-1 Programmed death-1, Tim-3 T cell
immunoglobulin mucin-3, Treg Regulatory T cell, MDSC Myeloid-derived
suppressor cell
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PD-1 and Tim-3 expression on CD8+ T cells was signifi-
cantly associated with a poor prognosis in only the HLA-
A*2402-matched group (p = 0.0046 and p = 0.0068,
respectively; Fig. 3h and 3k). These results also confirmed
our hypothesis that the expression of PD-1 and Tim-3 on
CD4+ and CD8+ T cells could be used as a biomarker for
immunotherapy outcome. Vaccine therapy is designed to
attack cancers by stimulating T cells and directing them to
recognize and act as TAA-specific T cells. In our study,
the expression of PD-1 and Tim-3 on both CD4+ and
CD8+ T cells was significantly upregulated in the short-
survival group after treatment. It is extremely difficult for
vaccine therapy to enhance immune responses in the im-
munosuppressive state, which may account for why there
might be no statistical difference between the HLA-
A*2402-matched group and the HLA-A*2402-unmatched
Fig. 3 Expression of biomarkers after 3rd cycle treatment. PD-1 and Tim-3 expression on CD4+ and CD8+ T cells obtained from patients in the
HLA-A*2402-matched group and the HLA-A*2402-unmatched group after the 3rd cycle of treatment. (a) Analysis for PD-1 expression in the
CD4+ lymphocyte gate. (b) In the HLA-A*2402-matched group, the percentage of PD-1+ CD4+ T cells in the patients of the short-survival group
(n = 19) was significantly higher than in the patients of the long-survival group (n = 6). (d) Analysis for Tim-3 expression in the CD4+ lymphocyte
gate. (e) In the HLA-A*2402-matched group, the percentage of Tim-3+ CD4+ T cells in the patients of the short-survival group was significantly
higher than in the patients of the long-survival group. (g) Analysis for PD-1 expression in the CD8+ lymphocyte gate. (h) In the HLA-A*2402-
matched group, the percentage of PD-1+ CD8+ T cells in the patients of the short-survival group was significantly higher than in the patients
of the long-survival group. (j) Analysis for Tim-3 expression in the CD8+ lymphocyte gate. (k) In the HLA-A*2402-matched group, the percentage
of Tim-3+ CD8+ T cells in the patients of the short-survival group was significantly higher than in the patients of the long-survival group
(p = 0.0068). (c), (f), (i), (l) In the HLA-A*2402-unmatched group, there was no difference in the percentages of PD-1+ and Tim-3+ CD4+ or CD8+
T cells between the patients with a long survival (n = 6) and the patients with a short survival (n = 15)
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group. Blockade of PD-1 and PD-L1 interactions can re-
verse T cell exhaustion and restore antigen-specific T cell
responses [38]. These results indicate that the combin-
ation of vaccine therapy with an immune checkpoint
blockade might be effective in advanced PC patients.
It has been reported that TIM-3 is co-expressed with
PD-1 on exhausted T cells [39, 40]. Our present study
also showed that the expressions of PD-1 and TIM-3 on
CD8 T cells were both significantly upregulated and had
a significant positive correlation after treatment (Fig. 3h,
3k and Additional file 3: FigureS2b). In this study,
although the upregulation of PD-1 expression on CD4+
cells was significantly associated with a poor clinical
outcome before treatment, there was no significant dif-
ference of Tim-3 (Table 2). These results may indicate
that TIM-3 could be expressed exclusively on T cells
that co-express PD-1, whereas, PD-1 expression might
not be required for Tim-3 co-expression.
It has been reported that high CTL responses to mul-
tiple peptides after vaccination are a possible biomarker
for a long survival in vaccinated patients [23, 29, 31]. In
this study, we observed that a low NLR and low number
of Tregs were also significantly associated with a high
CTL response (Table 3). Hence, we speculated that a
low NLR and number of Tregs may be related to pre-
dictive biomarkers. The NLR is an easily calculated and
simple marker of the systemic inflammatory response
[41]. Several studies have suggested that a high NLR is
associated with a poor prognosis in patients with various
cancers [18, 42, 43]. A decreased number of lymphocytes
diminishes the antitumor immune response and worsens
the prognosis [44]. However, the NLR was not signifi-
cantly correlated with a poor prognosis in this study, al-
though the small sample size may have accounted for this.
Tregs are considered to be one of the most powerful
inhibitors of antitumor immunity and is correlated with a
poor prognosis [45]. GEM has the potential to enhance the
antitumor effects of cancer immunotherapy by suppressing
the induction of Tregs and MDSCs [27, 46]. Although we
administered combination therapy with vaccine and GEM
in the present study, we did not find any significant de-
crease in these cell populations. These results indicate that
Tregs are not associated with a poor prognosis. Therefore,
the combination of immunotherapy and another chemo-
therapy that inhibits these immunosuppressive cells might
be attractive for advanced PC patients.
Conclusions
In conclusion, although the number of patients in this
study was very limited, a high expression level of PD-1
on CD4+ T cells may be a very promising biomarker for
predicting the prognosis of PC patients with vaccination.
The expression of PD-1 and Tim-3 on CD4+ and CD8+
T cells may also be a useful biomarker for predicting the
efficacy of cancer immunotherapy. Our results indicate
that the upregulation of PD-1 and Tim-3 expression on
CD4+ and CD8+ T cells may restrict T cell responses in
advanced PC patients. As such, combination immuno-
therapy with blockade of PD-1 and Tim-3 that restores
T cell responses may be a potential therapeutic approach
for treating advanced PC patients.
Additional files
Additional file 1: Figure S1. Positivity for antigen-specific T cell
responses was quantitatively defined according to the evaluation tree
algorithm. In brief, the peptide-specific spots (SS) were the averages of
triplicates calculated by subtracting the HIV peptide-pulsed stimulator
well from the immunized peptide-pulsed stimulator well. The %SS means
the percentage of SS among the average spots of the immunized
peptide-pulsed stimulator well. The antigen-specific T cell responses were
classified into four grades (−, +, ++, and +++) depending on the number
of peptide-specific spots and the invariability of the peptide-specific spots
at different responder/stimulator ratios. SS, peptide-specific spots; R1,
responder/stimulator ratio = 1; R2, responder/stimulator ratio = 0.5; R3,
responder/stimulator ratio = 0.25; R4, responder/stimulator ratio = 0.125.
(TIF 332 kb)
Additional file 2: Table S1. Comparison of prognostic factors according
to the numbers of peptide-specific responses (n = 36 HLA-A*2402-matched
patients). (DOCX 28 kb)
Additional file 3: Figure S2. Correlation between PD-1 and Tim-3
expression on CD4+ and CD8+ T cells in the patients with HLA-A*2402-
matched group after 3rd cycle treatment. (a) There was no correlation
between PD-1 and Tim-3 expression on CD4 T cells (r = 0.3015, p = 0.1430).
(b) PD-1 expression on CD8 T cells was significantly correlated with Tim-3
expression on CD8 T cells (r = 0.5385, p = 0.0055). (TIF 35 kb)
Additional file 4: Figure S3. Frequency of CD4+ CD45RA- CD25high
cells and CD11b + CD33+ cells. (a), (c) There were no differences in the
percentages of CD4+ CD45RA- CD25high cells and CD11b + CD33+ cells
in the 46 patients before and after treatment. (b), (e) Before and after
treatment, there were no differences in the percentages of CD4+
CD45RA- CD25high cells and CD11b + CD33+ cells between the patients
with a long survival (n = 6) and the patients with a short survival (n = 19)
in the HLA-A*2402-matched group. (c), (f) Before and after treatment,
there were no differences in the percentages of CD4+ CD45RA-
CD25high cells and CD11b + CD33+ cells between the patients with a
long survival (n = 6) and the patients with a short survival (n = 15) in the
HLA-A*2402-unmatched group. (TIF 60 kb)
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